Lonza Group (OTCMKTS:LZAGY) Upgraded by Royal Bank Of Canada to Moderate Buy Rating

Lonza Group (OTCMKTS:LZAGY) was upgraded by research analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research report issued on Wednesday,Zacks.com reports.

Separately, Zacks Research downgraded shares of Lonza Group from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Lonza Group Stock Down 2.3%

Shares of LZAGY opened at $65.63 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.46 and a debt-to-equity ratio of 0.48. Lonza Group has a 1 year low of $55.57 and a 1 year high of $73.85. The business’s 50 day simple moving average is $68.05 and its 200-day simple moving average is $68.53.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.